Medication does not help prevent ED following radiation therapy for prostate cancer

Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue of JAMA.

Erectile dysfunction (ED) is a common condition resulting from many causes, including treatment. An estimated 40 percent of men report ED after , and half of all men use erectile aids following this therapy. Tadalafil is used to treat after , but its role as a preventive agent has not been determined, according to background information in the article.

Thomas M. Pisansky, M.D., of the Mayo Clinic, Rochester, Minn., and colleagues with the Radiation Therapy Oncology Group, randomly assigned 242 men with prostate cancer to receive tadalafil (5 mg) or placebo daily for 24 weeks starting with radiation therapy (either with external radiotherapy [63 percent] or brachytherapy [37 percent]). The study was conducted at 76 sites in the United States and Canada; participants were recruited between November 2009 and February 2012, with follow-up through March 2013.

Between weeks 28 and 30 after the start of radiation therapy, among evaluable participants, 79 percent who received tadalafil retained erectile function compared with 74 percent who received placebo, an absolute difference of 5 percent. A significant difference between groups was also not observed at 1 year (72 percent vs 71 percent). Tadalafil was not associated with improved overall sexual function or satisfaction, and partners of men assigned tadalafil noted no significant effect on sexual satisfaction.

"These findings do not support the scheduled once-daily use of tadalafil to prevent ED in undergoing radiotherapy for localized prostate cancer," the authors write.

They add that alternative strategies to prevent ED in this context appear warranted, including different dosing or further refinements of radiation therapy delivery methods.

More information: DOI: 10.1001/jama.2014.2626

add to favorites email to friend print save as pdf

Related Stories

Predicting erectile dysfunction from prostate cancer treatment

Sep 27, 2012

Researchers have identified 12 DNA sequences that may help doctors determine which men will suffer from erectile dysfunction (ED) following radiation therapy for prostate cancer. Identifying these patients in advance of treatment ...

Are statins good for your love life?

Mar 29, 2014

Statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them, according to research to be presented ...

Recommended for you

New tool to probe cancer's molecular make-up

21 hours ago

Scientists have shown how to better identify and measure vital molecules that control cell behaviour – paving the way for improved tools for diagnosis, prediction and monitoring of cancer.

Mayo Clinic offers at-home colon cancer test

Aug 26, 2014

Mayo Clinic is taking another step toward making detection of colorectal cancer as convenient as possible, announcing Monday an at-home kit that arrives and is sent back in the mail, stool sample included.

Finding keys to glioblastoma therapeutic resistance

Aug 26, 2014

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas – the primary form of a deadly brain cancer – are resistant to drug therapy. The answer ...

No link found between diverticular disease, cancer

Aug 25, 2014

(HealthDay)—Colonic diverticular disease does not appear to be linked to an increased risk of subsequent colorectal cancer (CRC), according to research published in the August issue of Clinical Gastroenterology an ...

User comments